Tonix Pharmaceuticals Holding Corp (TNXP) concluded trading on Wednesday at a closing price of $34.32, with 0.41 million shares of worth about $13.95 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 42.70% during that period and on June 18, 2025 the price saw a loss of about -1.72%. Currently the company’s common shares owned by public are about 7.36M shares, out of which, 7.35M shares are available for trading.
Stock saw a price change of -8.99% in past 5 days and over the past one month there was a price change of 29.02%. Year-to-date (YTD), TNXP shares are showing a performance of 4.06% which decreased to -70.16% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $6.76 but also hit the highest price of $137.25 during that period. The average intraday trading volume for Tonix Pharmaceuticals Holding Corp shares is 1.21 million. The stock is currently trading -5.20% below its 20-day simple moving average (SMA20), while that difference is up 32.25% for SMA50 and it goes to 61.45% higher than SMA200.
Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) currently have 7.36M outstanding shares and institutions hold larger chunk of about 6.58% of that.
The stock has a current market capitalization of $252.50M and its 3Y-monthly beta is at 2.10. It has posted earnings per share of -$2930.78 in the same period. It has Quick Ratio of 11.64 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TNXP, volatility over the week remained 10.08% while standing at 8.66% over the month.
Stock’s fiscal year EPS is expected to rise by 93.08% while it is estimated to increase by 50.29% in next year. EPS is likely to grow at an annualized rate of 88.07% for next 5-years, compared to annual growth of 73.03% made by the stock over the past 5-years.
Coverage by ROTH Capital stated Tonix Pharmaceuticals Holding Corp (TNXP) stock as a Buy in their note to investors on April 18, 2019, suggesting a price target of $4 for the stock. Stock get an Outperform rating from Oppenheimer on February 17, 2016.
